# Diagnostic accuracy evaluation of individual or combinational fecal immunochemical test, M3 gene, KRAS mutation and tumor methylation burden in colorectal carcinoma

**Authors:** Junyue Xu, Shuai Chen, Hongxia Niu, Yahong Zhao, Xiaohong Wu, Yi Li, Shana Zhang

PMC · DOI: 10.3389/fimmu.2025.1627130 · Frontiers in Immunology · 2025-07-23

## TL;DR

This study evaluates combinations of tests for diagnosing colorectal cancer, finding that combining M3 gene, methylation, and KRAS mutation tests improves accuracy, especially for early detection.

## Contribution

The study introduces a novel combination of M3 gene expression, methylation burden, and KRAS mutation for improved early colorectal cancer diagnosis.

## Key findings

- Combining M3 gene expression, methylation burden, and KRAS mutation achieved the highest diagnostic accuracy (AUC: 0.920).
- The combination was particularly effective for early CRC patients (AUC: 0.931).
- Adding fecal immunochemical test (FIT) did not improve performance beyond the three-marker combination.

## Abstract

This study is aimed to develop multivariate prediction method in colorectal cancer (CRC) diagnosis.

M3 gene expression was determined using Fecal DNA extraction kits and performed by qRT-PCR. Methylation-burden and KRAS-mutation were detected by using the corresponding kits. Receiver operating characteristic curve analysis and the area under the curve (AUC) was calculated to evaluate diagnostic performance using SPSS software.

197 of CRC samples were enrolled to screen the best predictive combination among fecal immunochemical test (FIT), M3 expression and KRAS-mutation in feces, and Methylation-burden in blood. Single factor analysis showed that M3 expression showed the best diagnosis performance and fecal immunochemical test (FIT) showed the lowest AUC. Combination of two makers universally enhanced diagnostic performance, of which Methylation-burden and M3 alliance displayed the highest AUC value. Interestingly, combination of M3, Methylation-burden and KRAS-mutation reached the best performance for all patients (AUC: 0.920), especially for early CRC patients (AUC: 0.931), which possessed the same predictive efficiency with the combination of four factors.

Combined application of M3, Methylation-burden and KRAS-mutation might be the most reliable method for early CRC diagnosis.

## Linked entities

- **Genes:** m3 (Holliday junction resolvase) [NCBI Gene 1261737], KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845]
- **Diseases:** colorectal carcinoma (MONDO:0024331), colorectal cancer (MONDO:0005575)

## Full-text entities

- **Genes:** KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}
- **Diseases:** tumor (MESH:D009369), CRC (MESH:D015179)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12325307/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12325307/full.md

## References

32 references — full list in the complete paper: https://tomesphere.com/paper/PMC12325307/full.md

---
Source: https://tomesphere.com/paper/PMC12325307